TRANSCATHETER AORTIC VALVE REPLACEMENT

THE EVOLUT™ Hemodynamic ADVANTAGE 

The Evolut TAV's supra-annular, self-expanding valve design delivers exceptional hemodynamics and is the only TAVR device to demonstrate hemodynamic superiority in a low risk clinical trial vs. SAVR.1

SEE THE HEMODYNAMIC ADVANTAGE
need
Alert Important Safety Information

Evolut™ TAVR Platform    Cusp Overlap Technique Precision & Control

LEARN MORE
need

TAVR LITERATURE

Hemodynamics

pdf IN VITRO HEMODYNAMIC DATA FROM ACC.2020 (.pdf)

518KB

IN VITRO HEMODYNAMIC DATA FROM ACC.2020
pdf VIVID REGISTRY HEMODYNAMICS IN TAV-N-SAV PATIENTS (.pdf)

357KB

VIVID REGISTRY HEMODYNAMICS IN TAV-N-SAV PATIENTS

TAVR PROCEDURE

pdf CUSP OVERLAP TECHNIQUE BROCHURE (.pdf)

507KB

CUSP OVERLAP TECHNIQUE BROCHURE
pdf CUSP OVERLAP TIP CARD (.pdf)

588KB

CUSP OVERLAP TIP CARD

PATIENT SELECTION

pdf LOW RISK BICUSPID ONE-PAGER* (.pdf)

449KB

LOW RISK BICUSPID ONE-PAGER*
pdf EVOLUT LOW RISK ONE-PAGER (.pdf)

1.1MB

EVOLUT LOW RISK ONE-PAGER

RESOURCES FOR HEART VALVE PATIENT CONVERSATIONS

pdf ACTIVE LIVING SURVEY RESOURCE OVERVIEW (.pdf)

209KB

ACTIVE LIVING SURVEY RESOURCE OVERVIEW
CONTACT

Would you like to learn more about Medtronic products?

Contact us
Access Educational Resources on Medtronic Academy
*

Limited clinical data are available for transcatheter aortic valve replacement in patients with a congenital bicuspid aortic valve who are deemed to be at low surgical risk. Anatomical characteristics should be considered when using the valve in this population. In addition, patient age should be considered as long-term durability of the valve has not been established.

Reference

1

Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.